Skye Bioscience Inc. said Chief Financial Officer Kaitlyn Arsenault will step down effective February 20, 2026, to pursue new opportunities. The company will retain Arsenault as an advisor for transition-related services. Skye Bioscience President and CEO Punit Dhillon was appointed principal accounting officer effective February 20, 2026, while continuing in his current roles.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-010186), on February 20, 2026, and is solely responsible for the information contained therein.